Abstract | BACKGROUND: AIM: DESIGN: The Indobufen vs Aspirin in Acute Ischaemic Stroke (INSURE) is a randomised, double-blind, double-dummy, positive drug control, non-inferior multicentre clinical trial conducted in 200 hospitals in China. Participants will be randomised at a 1:1 ratio to receive either 100 mg indofufen two times daily or 100 mg aspirin once daily within 72 hours of the onset of symptoms from day 1 to 3 months. STUDY OUTCOMES: The primary efficacy outcome is a new stroke (ischaemic or haemorrhagic) within 3 months and the primary safety outcome is a severe or moderate bleeding event within 3 months. DISCUSSION: TRIAL REGISTRATION NUMBER: NCT03871517.
|
Authors | Yuesong Pan, Xia Meng, Weiqi Chen, Jing Jing, Jinxi Lin, Yong Jiang, S Claiborne Johnston, Philip M Bath, Qiang Dong, An-Ding Xu, Hao Li, Yongjun Wang |
Journal | Stroke and vascular neurology
(Stroke Vasc Neurol)
Vol. 7
Issue 5
Pg. 457-461
(10 2022)
ISSN: 2059-8696 [Electronic] England |
PMID | 35393360
(Publication Type: Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Aspirin
- Platelet Aggregation Inhibitors
- indobufen
|
Topics |
- Humans
- Aspirin
(adverse effects)
- Platelet Aggregation Inhibitors
(adverse effects)
- Brain Ischemia
(diagnosis, drug therapy)
- Stroke
(diagnosis, drug therapy, prevention & control)
- Treatment Outcome
- Ischemic Stroke
(diagnosis, drug therapy)
- Hemorrhage
(chemically induced)
|